Publications by authors named "Jean-Pierre Vilque"

Claim this Profile
L
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Sylvain Carras, Alexia Torroja, Anouk Emadali, Emilie Montaut, Nicolas Daguindau, Jean Pierre Vilque

Haematologica· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial.
Michael Lübbert, Pierre W Wijermans, Michal Kicinski, Sylvain Chantepie, Walter J F M Van der Velden, Jean-Pierre Vilque

Lancet Haematol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.
Anne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, Lydia Campos, Michel Ticchioni, Jean-Pierre Vilque

Blood Adv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
End-of-treatment F-FDG PET/CT in diffuse large B cell lymphoma patients: ΔSUV outperforms Deauville score.
François Allioux, Damaj Gandhi, Jean-Pierre Vilque, Cathy Nganoa, Anne-Claire Gac

Leuk Lymphoma· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic value of baseline FDG PET/CT skeletal textural features in follicular lymphoma.
Julie Faudemer, Nicolas Aide, Anne-Claire Gac, Ghandi Damaj, Jean-Pierre Vilque

Sci Rep· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database.
Joachim Alexandre, Joe-Elie Salem, Javid Moslehi, Marion Sassier, Camille Ropert, Jean-Pierre Vilque

Eur Heart J Cardiovasc Pharmacother· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
Anne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, Carmen Aanei, Michel Ticchioni, Jean-Pierre Vilque

Blood· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful Imatinib therapy as a bridge to transplant in an atypical myeloproliferative neoplasm.
Thomas Hueso, Hyacinthe Johnson-Ansah, Matthieu Decamp, Elsa Maitre, Alexandra Henry, Jean-Pierre Vilque

Curr Res Transl Med· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.
Rémy Gressin, Nicolas Daguindau, Adrian Tempescul, Anne Moreau, Sylvain Carras, Jean Pierre Vilque

Haematologica· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients.
Sylvain Chantepie, Narinée Hovhannisyan, Stéphane Guillouet, Jean-Pierre Pelage, Méziane Ibazizene, Jean-Pierre Vilque

J Nucl Med· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers.
Sylvain P Chantepie, Sylvain Garciaz, Emmanuelle Tchernonog, Frederic Peyrade, Marie-Virginie Larcher, Jean-Pierre Vilque

Am J Hematol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.
Caroline Dartigeas, Eric Van Den Neste, Julie Léger, Hervé Maisonneuve, Christian Berthou, Jean-Pierre Vilque

Lancet Haematol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased frequencies of circulating and tumor-resident Vδ1 T cells in patients with diffuse large B-cell lymphoma.
Emilie Reboursiere, Anne-Claire Gac, Anthony Garnier, Véronique Salaun, Oumedaly Reman, Jean-Pierre Vilque

Leuk Lymphoma· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.
Anne-Sophie Michallet, Arnaud Campidelli, Helene Lequeu, Marie-Sarah Dilhuydy, Olivier Tournilhac, Jean-Pierre Vilque

Am J Hematol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic value of hematogones in patients with acute myeloid leukemia.
Sylvain P Chantepie, Jean-Jacques Parienti, Véronique Salaun, Khaled Benabed, Stéphane Cheze, Jean-Pierre Vilque

Am J Hematol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia.
Sylvain P Chantepie, Emilie Reboursiere, Jean-Baptiste Mear, Anne-Claire Gac, Veronique Salaun, Jean-Pierre Vilque

Leuk Lymphoma· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia.
Caroline Dartigeas, Eric Van Den Neste, Christian Berthou, Hervé Maisonneuve, Stéphane Leprêtre, Jean-Pierre Vilque

Leuk Lymphoma· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transfusion strategy in hematological intensive care unit: study protocol for a randomized controlled trial.
Sylvain P Chantepie, Jean-Baptiste Mear, Lydia Guittet, Benoît Dervaux, Jean-Pierre Marolleau, Jean-Pierre Vilque

Trials· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.
Philippe Rodon, Cyrille Hulin, Brigitte Pegourie, Mourad Tiab, Bruno Anglaret, Jean-Pierre Vilque

Haematologica· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The importance of harmonizing interim positron emission tomography in non-Hodgkin lymphoma: focus on the Deauville criteria.
Elske Quak, Narinée Hovhannisyan, Charline Lasnon, Christophe Fruchart, Jean-Pierre Vilque

Haematologica· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
Gandhi Damaj, Rémy Gressin, Krimo Bouabdallah, Guillaume Cartron, Bachra Choufi, Jean-Pierre Vilque

J Clin Oncol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hematogones: a new prognostic factor for acute myeloblastic leukemia.
Sylvain P Chantepie, Véronique Salaün, Jean-Jacques Parienti, Florence Truquet, Margaret Macro, Jean Pierre Vilque

Blood· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.
Audrey Simon, Michel Peoch, Philippe Casassus, Eric Deconinck, Philippe Colombat, Jean Pierre Vilque

Br J Haematol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group.
Rémy Gressin, Sylvie Caulet-Maugendre, Eric Deconinck, Olivier Tournilhac, Emmanuel Gyan, Jean Pierre Vilque

Haematologica· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years.
Emmanuel Gyan, Charles Foussard, Philippe Bertrand, Patrick Michenet, Steven Le Gouill, Jean-Pierre Vilque

Blood· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis